Cellromax Science셀로맥스사이언스
471820 · KOSDAQ · ₩471820 · 셀로맥스사이언스
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩3,952
vs the current price (₩3,965)
- Enterprise value
- ₩40B
- Equity value
- ₩45B
- WACC
- 7.4%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Bear / Base / Bull
- Bear
- ₩2,738
- −30.9%
- Base
- ₩3,952
- −0.3%
- Bull
- ₩5,992
- +51.1%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (16.4%).
Revenue growth
- 2.6%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
- 2.7%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
- 2.8%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
- 2.9%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
Business
- 16.4%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 5.4%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 6.8%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).
- 40%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.08%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-29.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 98 weeks of weekly returns against KOSPI (official index); raw beta 0.18, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.58%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩20B
- Net debt (borrowings and leases − cash and deposits)
- −₩5.1B
- Shares
- 11,302,879
- Share price
- ₩3,965
- Market cap
- ₩45B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|
| Revenue | ₩22B | ₩22B | ₩20B | ₩21B | ₩21B | ₩22B | ₩23B |
| Growth | — | 2.6% | 2.6% | 2.7% | 2.8% | 2.9% | 3.0% |
| EBIT | ₩5.5B | ₩2.8B | ₩3.3B | ₩3.4B | ₩3.5B | ₩3.6B | ₩3.7B |
| EBIT margin | 25.4% | 12.8% | 16.4% | 16.4% | 16.4% | 16.4% | 16.4% |
| After-tax EBIT | ₩4B | ₩2.1B | ₩2.4B | ₩2.5B | ₩2.5B | ₩2.6B | ₩2.7B |
| + Depreciation | — | — | ₩1.1B | ₩1.1B | ₩1.1B | ₩1.2B | ₩1.2B |
| − Capital spending | ₩2.8B | ₩179M | ₩1.4B | ₩1.4B | ₩1.4B | ₩1.5B | ₩1.5B |
| − Working capital | — | −₩3B | ₩204M | ₩217M | ₩231M | ₩246M | ₩262M |
| Free cash flow | — | — | ₩1.9B | ₩1.9B | ₩2B | ₩2B | ₩2.1B |
| Discount factor | — | — | 0.931 | 0.867 | 0.808 | 0.752 | 0.700 |
| Present value | — | — | ₩1.8B | ₩1.7B | ₩1.6B | ₩1.5B | ₩1.5B |
Terminal value ₩45B, worth ₩32B today: 80% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.4% | ₩4,186 | ₩4,450 | ₩4,772 | ₩5,177 | ₩5,702 |
| 6.9% | ₩3,857 | ₩4,067 | ₩4,320 | ₩4,630 | ₩5,018 |
| 7.4% | ₩3,580 | ₩3,750 | ₩3,952 | ₩4,194 | ₩4,491 |
| 7.9% | ₩3,343 | ₩3,483 | ₩3,647 | ₩3,840 | ₩4,072 |
| 8.4% | ₩3,139 | ₩3,255 | ₩3,389 | ₩3,546 | ₩3,731 |
Now (TTM)
- Market cap
- ₩45B
- Enterprise value
- ₩39B
- P/E
- 11.8×
- P/B
- 1.0×
- P/S
- 2.3×
- EV/EBITDA
- —
- Dividend yield
- 4.7%
Over time (at each year end)
| 2025 | 2024 | |
|---|---|---|
| Price | ₩6,500 | ₩4,915 |
| Market cap | ₩73B | ₩56B |
| P/E | 24.8× | 14.6× |
| P/B | 1.6× | 1.2× |
| P/S | 3.3× | 2.6× |
| EV/EBITDA | — | — |
| Dividend yield | 2.8% | 3.4% |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Cellromax Science | 11.8× | 1.0× | 2.3× | — | 4.7% |
| Samyang Foods | 17.6× | 5.6× | 3.1× | — | 0.4% |
| Orion | 10.6× | 1.1× | 1.2× | 5.3× | 3.1% |
| CJ Cheiljedang | — | 0.3× | 0.1× | — | 3.5% |
| Nongshim | 12.0× | 0.8× | 0.6× | — | 1.5% |
| Otoki | 17.3× | 0.6× | 0.3× | — | 2.9% |
| Hite Jinro | 23.2× | 0.9× | 0.4× | 6.4× | 4.5% |
| Similar companies (median) | 17.3× | 0.9× | 0.5× | 5.8× | 3.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Cellromax Science / 셀로맥스사이언스 / 471820 / KRX:471820
Source: KRX statistical information